Company Overview
About SHINE Technologies
SHINE Technologies is a Janesville, Wisconsin-based company that is commercializing fusion technology for practical near-term applications — starting with medical isotope production, nuclear waste characterization, and industrial component inspection. Unlike fusion energy companies pursuing electricity generation as their first market, SHINE has built a phased commercialization strategy: its fusion neutron systems produce the radioisotopes used in medical imaging and cancer treatment today, generating commercial revenue while advancing the underlying fusion technology toward energy applications.
Business Model & Competitive Advantage
SHINE''s Chrysalis facility, currently 75–80% complete, will establish the first domestic commercial supply of molybdenum-99 (Mo-99) — the parent isotope of technetium-99m, which is used in more than 40,000 nuclear medicine diagnostic procedures every day in the United States. The U.S. currently imports virtually all of its Mo-99 supply, creating significant national security and healthcare supply chain vulnerabilities. In April 2026, the U.S. Department of Energy''s Office of Energy Dominance Financing conditionally committed $263 million in loan financing to complete the Chrysalis facility, which is expected to become fully operational in 2028.
Competitive Landscape 2025–2026
Beyond Mo-99, SHINE''s fusion neutron platform is designed to produce a range of critical radioisotopes including iodine-131 and xenon-133, as well as to characterize nuclear waste and inspect industrial components using neutron imaging. SHINE has received backing from strategic and financial investors and has cultivated deep relationships with the U.S. government''s nuclear medicine supply chain stakeholders, including the National Nuclear Security Administration (NNSA). The company is led by CEO Greg Piefer, one of its original founders.
Key Differentiators
Strong Challenger
SHINE Technologies is an established challenger with significant market presence and competitive offerings in Life Sciences & BioTech.
Frequently Asked Questions
Similar Brands
Neuralink
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with pa
BioNTech
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere
Genentech
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching
Illumina
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat
Regeneron
Regeneron Pharmaceuticals was founded in 1988 in Tarrytown, New York by Leonard Schleifer and George Yancopoulos. The company built its reputation on the Velocimmune platform—a proprietary humanized m
Pliant Therapeutics
Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (IPF), primary sclero
Compare SHINE Technologies with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from SHINE Technologies? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim SHINE Technologies Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention SHINE Technologies vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →